Medicinal Cannabis Matters: Friday Roundup - 6 February 2026
Welcome to this week’s round-up in medicinal cannabis, where emerging research and patient-focused discussion continue to shape a more informed understanding of medicinal cannabis care. This week’s stories explore how low-dose cannabinoids are being studied in neurodegenerative disease, what new research says about cannabis use and brain health in later life and why clearer guidance around lawful use remains essential for patients in the UK.
Low-Dose THC and Anti-Inflammatory Treatment in Alzheimer's Research
New research reported by Cannabis Health News highlights promising findings around the combined use of low-dose THC and a commonly prescribed anti-inflammatory drug in Alzheimer's disease. The study suggests that, when used together, these treatments may help reduce neuroinflammation and slow cognitive decline, a significant focus area given the limited effectiveness of current therapies.
Importantly, the research centres on low-dose, carefully controlled THC, reinforcing the principle that medicinal cannabis is about targeted, clinically guided intervention. While further trials are needed, the findings add to growing evidence that cannabinoids may play a role in managing complex neurological conditions where inflammation and cognitive deterioration intersect.
Cannabis Use Linked to Brain Health in Older Adults
A separate study from researchers at the University of Colorado Anschutz Medical Campus has explored cannabis use in middle-aged and older adults, with findings suggesting an association between cannabis use and larger brain volume, alongside better cognitive performance in certain areas.
While the authors are careful to note that correlation does not equal causation, the results challenge long-standing assumptions that cannabis use is inherently damaging to cognitive health in later life. Instead, the research opens the door to more nuanced discussion around dosage, formulation and therapeutic context, particularly for older patients managing chronic conditions such as pain, sleep disruption or neurological symptoms.
The Medical Cannabis Paradox
An article from Leafie this week examines what it calls the "medical cannabis paradox": the ongoing confusion many UK patients face around what is legal, appropriate and protected under current regulations. While medicinal cannabis has been legal in the UK since 2018, misunderstandings around possession, use in public spaces and employment rights remain common.
This lack of clarity can create unnecessary anxiety, even when they are prescribed treatment lawfully. The article highlights the importance of patient education, professional guidance and consistent messaging, ensuring individuals feel confident using their medication as intended, without fear or stigma.
This week's stories reflect a broader shift in how medicinal cannabis is being studied, discussed and understood. From emerging neurological research to clearer conversations about patient rights, the focus continues to move towards evidence-based care and practical support for those navigating treatment options.
As research evolves and awareness grows, the conversation around medicinal cannabis is becoming less about debate and more about outcomes, safety and quality of life.
If you are considering whether medicinal cannabis may be suitable for your condition, the first step is to check your eligibility. Medicann's online eligibility checker takes just a couple of minutes to complete and provides a clear, confidential starting point for patients across the UK and Channel Islands.
Disclaimer: This blog post and the following featured articles are for information only and any articles on external platforms may be amended at any time. Articles that we refer to in our weekly roundup do not reflect the views of Medicann.